Editor’s note: Every biotech investor knows the Novo Nordisk story. Ozempic. Wegovy. The 100-year-old Danish company that briefly became the most valuable company in Europe. What most people miss is the corporate structure sitting beneath all of it. A foundation that owns most of the voting rights. A charitable trust that built the moat. And, quite possibly, the same trust that is now stopping the company from climbing out of the hole it is in.
PREMIER FEATURE
The REAL Reason 2,000 Missiles Rained on Iran
Forget terrorism. Forget oil prices. Forget everything the evening news told you.
After two private meetings with U.S. Congressmen on March 2nd — and weeks of digging into what those conversations uncovered — I'm convinced we launched those strikes for a completely different reason.
If you have even a single dollar invested in the U.S. stock market, what I've found will directly impact you — starting August 12th.
But before we get to that, let's take a quick look at the markets and what matters…
Markets are shrugging off the war. Oil is falling even as the US and Iran keep trading fire, and the hawkish Fed minutes, not the Middle East, are now the story with staying power.
3 Movers in 3 Minutes
The war rally faded, again. Oil fell even as the US struck 90 more Iranian targets overnight. Brent slipped toward $77 and WTI toward $73 after President Trump said Iran called seeking a deal. The VIX dropped back below 17 from near 19 on Wednesday. This is the fourth direction oil has taken in four sessions, from glut to Hormuz spike to a 6% war jump and now a fade. The market has decided a lasting truce is still in both sides' interest.
Chips bounced off the bear-market low. A day after the Kospi entered a bear market, semis rallied worldwide. Micron (MU) and Marvell (MRVL) each rose about 4% premarket, Intel (INTC) about 3%, and Europe's ASML and STMicro gained 2 to 4%. SK Hynix closed up 5% in Seoul. One session of panic, one session of "normal consolidation," in BNP's words. The AI trade keeps refusing to break.
Another beat got sold. Levi Strauss (LEVI) beat earnings, raised its dividend, and lifted its sales outlook, and the stock still fell about 5%. That makes four this week: Nike, Tesla, Samsung, now Levi. When expectations are set this high, good news is not good enough. The bar, not the result, is moving the tape.
3 Signals for Today
SK Hynix prices today, trades Friday. The memory maker's US listing is more than seven times oversubscribed, on track to be the second-biggest share sale ever, behind only SpaceX's $85.7 billion IPO last month. The stock is up 680% in a year, yet its forward P/E has fallen to 5.5 from 7.9, because earnings outran the price. Watch the pricing this afternoon for how much AI-memory appetite is really left.
Williams and Logan speak after hawkish minutes. Wednesday's June minutes showed a few members wanted a hike and the committee split on rates, with one read calling a September hike "wide open." New York Fed's Williams at 9:00 AM ET and Dallas Fed's Logan at 1:30 PM are the first officials to talk since. Any hike language moves the front end.
Jobless claims at 8:30 AM ET. The week's cleanest labor read, and it matters more now that the hike debate is live. A soft print complicates the hawkish case. A firm one hands it more room.
FROM OUR SPONSORS
Why are companies flying spy planes over Elon's closely-guarded AI lab?
Elon did the seemingly impossible – far faster than anyone expected...
ChatGPT, Claude, Google Gemini, and DeepSeek could soon become obsolete.
And three little-known firms could soar 10X or higher as a result.
And with that out of the way, here's today's big story: why the company that invented the weight loss boom is now struggling to survive it, and why the answer sits in a charitable trust in Copenhagen.
The Sip
In the autumn of 1922, a Danish physiologist named August Krogh boarded a ship to North America.
He had just won the Nobel Prize in Medicine, and his lecture tour was going to take him from Boston to Toronto and back home to Copenhagen.
His wife, Marie, was on that ship too.
She was one of Denmark's first female medical doctors. She was also, quietly, dying.
Marie had Type 2 diabetes at a time when diabetes was still a death sentence. A few months before the trip, a lab in Toronto had done something the world had considered impossible... they had manufactured a hormone called insulin. Marie asked her husband to detour.
He did. And in March 1923, the first Danish patient was treated with insulin produced in a small Copenhagen lab called Nordisk Insulinlaboratorium.
It was a love story. It was also a business. Krogh, in agreement with the researchers in Toronto, set it up under a foundation. The profits were to fund research and humanitarian work. Not shareholders.
That decision, made in a Copenhagen boardroom over a century ago, is the reason we are writing this story today.
Purpose is a moat. Until it isn't.
For most of the 20th century, Novo Nordisk was a diabetes company. A very good one, but nothing that most people outside pharma had ever heard of. Insulin pens. Long research cycles. Modest returns.
Then came semaglutide.
You already know what happened next. Ozempic in 2017. Wegovy in 2021. Weight loss went from being a discretionary indulgence to a chronic disease category. And by September 2024, Novo Nordisk was worth more than $650 billion, briefly overtaking LVMH as Europe's most valuable listed company. A Danish insulin maker had outrun French luxury.
And here's what nobody was really talking about at the time.
Novo Nordisk's parent foundation, the Novo Nordisk Foundation, controls roughly 77% of the voting rights of the company. Not the shares... the votes. Ordinary public shareholders own most of the equity but almost none of the say. The foundation exists to fund science and public health. It does not exist to please Wall Street.
That structure was Novo's superpower. It let the company spend 30 years grinding through peptide chemistry when American pharma had already moved on. It funded insulin analogues and semaglutide long past the point at which a normal CEO would have been fired for the R&D bill.
Every great biotech breakthrough looks like patience in hindsight. In real time, it looks like burning money.
Then the game changed.
Same DNA. Different game.
Eli Lilly did not invent GLP-1s. It invented something better.
Tirzepatide, the molecule inside Mounjaro and Zepbound, hits two hormone receptors at once. GLP-1 and GIP. In head-to-head trials, it produced 20.2% average weight loss versus 13.7% for Wegovy. Then Novo stumbled on its own.
The unwind started back in late 2024, when CagriSema, Novo's next big obesity hope, hit 22.7% weight loss against a 25% target the company had set itself. Superior to its parts, but short of the bar. The stock sold off hard, and the slide from the 2024 peak began. The cruel part: the drug worked. It just missed the number Novo had promised.
Today, Lilly holds more than 60% of the US obesity drug market. Novo's stock is down about 75% from its 2024 peak, and down roughly 44% in the past year alone. The company is now worth about $164 billion, against Lilly's $1.1 trillion.
The gap shows up in the growth rates. In the first quarter of 2026, Novo's Wegovy franchise grew 22%. Lilly's Mounjaro and Zepbound grew 125% and 80%. Same market, same quarter, opposite trajectories.
The obvious story is that Lilly had a better molecule. Which is true, but it isn't the whole story.
The deeper story is that Lilly bought its way into position. Loxo Oncology. Point Biopharma. Eli Lilly acquired multiple mechanisms and multiple platforms across two decades. It is a pharma conglomerate that treats molecules like assets in a portfolio.
Novo Nordisk did the opposite. It bet everything on one platform. One molecule. Semaglutide, twisted into new indications, new dosages, new delivery methods. That is what a foundation-controlled company with a purpose statement does. It goes deep. It does not go wide.
The pill that might rewrite the ending
There is one twist worth flagging.
Novo launched oral Wegovy, the first oral GLP-1 for obesity, and it has written more than 3 million US prescriptions in about five months. The pill is pulling in patients who refused needles, expanding the market rather than just shifting existing users. For a moment, it looks like the foundation strategy might work again.
Except there is a catch. Novo has guided to falling sales and operating profit in 2026, its first real decline of the GLP-1 era. Pharmacy benefit managers are steering patients toward Lilly. And retatrutide, Lilly's triple-agonist that hit 28.7% weight loss in trials, is still coming.
The pill buys time. It does not restore the crown.
Long Angle
Every company eventually meets a moment where the machine that built it becomes the machine that constrains it.
For Novo, that machine is the foundation. A structure that let a small Danish lab spend a century turning one class of proteins into some of the most important drugs in human history. A structure that made shareholder impatience irrelevant, because the shareholders did not control the votes.
The problem is that the same structure makes it very hard to become something else. You cannot acquihire your way to a new pipeline when your voting shareholder is a charitable trust with its own priorities. You cannot pivot the way Lilly has, because you are not built to pivot. You are built to persist.
And so Novo is doing what it has always done. Grinding forward on the next molecule, the next delivery system, the next indication. Betting that patience, once again, is the moat.
Right now that means repositioning semaglutide as a longevity and cardiometabolic platform, not just a weight loss drug, and pushing amycretin, its next dual-agonist, through Phase 3. Going deeper on the molecule it already owns, rather than buying its way into a new one. The same move as always.
The bulls have a case: the stock is cheap at about 10 times earnings, the pill is real, and Novo has been counted out before.
History has been kind to this bet before.
Whether it works this time depends on something nobody at Novo controls. Whether the market for weight loss rewards the deepest thinker in the room, or the fastest.
PARTNER SPOTLIGHT
Middle East Conflict Lights Fuse on US Debt Bomb
America was already drowning in $38 trillion of debt, but the recent conflict in the Middle East just accelerated the timeline.
As oil spikes, a 100-year-old stock market signal that accurately predicted the 2008 and 2020 crashes is flashing a massive "Sell" on dozens of popular U.S. equities.
If you hold the wrong stocks when this debt crisis hits, it could wipe out years of gains.
11780 US Highway 1, Palm Beach Gardens, FL 33408-3080 Would you like to edit your e-mail notification preferences or unsubscribe from our mailing list? Copyright © 2026 Weiss Ratings. All rights reserved.
The MarketSips Takeaway
The best corporate structures are not the ones that maximize flexibility. They are the ones that match the tempo of the game being played. Novo Nordisk was built for a slow game. The weight loss market is not a slow game. That mismatch is the entire story, and it is the frame worth carrying into every biotech thesis from here.
Reply and tell us: when a company's advantage becomes its cage, is the right move to fix the cage or change the game?
Until then, sip slowly!
The Market Sip Desk
